These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24643982)

  • 1. What's next for Alzheimer treatment?: while Aβ isn't out of the picture yet, several other therapeutic routes are being explored.
    Schwartz A
    Ann Neurol; 2013 Apr; 73(4):A7-9. PubMed ID: 24643982
    [No Abstract]   [Full Text] [Related]  

  • 2. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.
    Adalbert R; Gilley J; Coleman MP
    Trends Mol Med; 2007 Apr; 13(4):135-42. PubMed ID: 17344096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.
    Small SA; Duff K
    Neuron; 2008 Nov; 60(4):534-42. PubMed ID: 19038212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer's disease.
    Porzoor A; Macreadie IG
    J Alzheimers Dis; 2013; 35(2):217-25. PubMed ID: 23396350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications.
    Kaplitt M; Gouras GK; Makimura H; Jovanovic J; Sweeney D; Greengard P; Relkin NR; Gandy S
    Ann N Y Acad Sci; 1996 Dec; 802():42-9. PubMed ID: 8993483
    [No Abstract]   [Full Text] [Related]  

  • 6. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
    FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How
    Underwood E
    Science; 2017 Sep; 357(6357):1224. PubMed ID: 28935785
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunction and Alzheimer's disease.
    Maruszak A; Żekanowski C
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):320-30. PubMed ID: 20624441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.
    Martiskainen H; Haapasalo A; Kurkinen KM; Pihlajamäki J; Soininen H; Hiltunen M
    Expert Opin Ther Targets; 2013 Jul; 17(7):781-94. PubMed ID: 23573918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.
    Huang Y
    Trends Mol Med; 2010 Jun; 16(6):287-94. PubMed ID: 20537952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial.
    Kullmann DM
    Brain; 2016 May; 139(Pt 5):1311. PubMed ID: 27189576
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau.
    Stoppelkamp S; Bell HS; Palacios-Filardo J; Shewan DA; Riedel G; Platt B
    Exp Neurol; 2011 Jun; 229(2):226-37. PubMed ID: 21295028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation therapeutics for Alzheimer's disease.
    Bredesen DE; John V
    EMBO Mol Med; 2013 Jun; 5(6):795-8. PubMed ID: 23703924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane trafficking pathways in Alzheimer's disease.
    Rajendran L; Annaert W
    Traffic; 2012 Jun; 13(6):759-70. PubMed ID: 22269004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power tools for Alzheimer's disease - an electrochemical preamp for Aβ.
    Zetterberg H; Hammarström P
    J Neurochem; 2012 Jul; 122(2):231-2. PubMed ID: 22409410
    [No Abstract]   [Full Text] [Related]  

  • 20. Spatial Distribution of Tau and β-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes.
    Palmqvist S; Eshaghi A
    Neurology; 2021 Feb; 96(5):191-192. PubMed ID: 33262229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.